HAE Canada
2935 Conroy Rd. #110 K1G 6C6 Ottawa, ON, Canada

To celebrate the 10th anniversary of HAE Day, we are asking the entire Canadian HAE community to please take part in the global awareness campaign organized by HAEi: "Let’s Take the Next Step for HAE". This year they have made it even easier to participate. All you need to do is go on the HAE Day :-) website, and there you can regularly record the time you spend on physical or wellbeing activities. The website will then convert your activities (which includes anything from w...alking, to yoga, to painting, to reading even) into steps. https://haeday.org/ The country with the most steps taken between now and HAE Day, wins the walk. Canada won last year - please help us win again in 2021! #active4hae

We love sharing amazing news, and now we have even more to love! On March 17th, 2021, lanadelumab (TAKHZYRO), a subcutaneous monoclonal antibody inhibitor of plasma kallikrein, was added to the Newfoundland & Labrador Prescription Drug Program (NLPDP) benefit list; giving eligible HAE patients access to this new treatment. Thank you to the dedicated team at Takeda Canada and to the Newfoundland & Labrador provincial government who both worked hard to give HAE patients access... to this treatment in Newfoundland and Labrador. Please click below to view our website post that contains a link to the province’s Bulletin where you can learn more about accessing this prophylaxis (preventative) treatment in Newfoundland & Labrador. https://haecanada.org/takhzyro-now-available-in-newfoundla/

We are thrilled to let you know that starting April 6, HAEGARDA, a subcutaneous C1 Esterase Inhibitor (human), manufactured by CSL Behring, will be included on the Canadian Blood Services (CBS) formulary. This means that all eligible HAE patients across Canada will be able to access this treatment. This accomplishment did not happen over night; there were many steps taken to reach this amazing point in the road. We are proud that HAE Canada was part of one of these steps by p...roviding a Patient Submission to CBS to help illustrate the importance this treatment is for patients. We want to extend a huge thank you to all our members who participate in our surveys; the data we collect is used to develop our submissions. https://haecanada.org/hae-canada-patient-submissions/ We want to thank the team at CSL Behring who worked extremely hard to bring this treatment to Canadian HAE patients. We are truly grateful for their dedication and commitment. Also, we want to thank the team at CBS who gave HAE Canada the opportunity to advocate for HAE patients across the country. Thank you for listening to patients who shared their stories and experiences and for ultimately adding this treatment to the CBS formulary, allowing equitable access to patients across Canada. Please click the link below to view CBS’s Dear Customer Letter (DCL) on their website, indicating that healthcare providers will be able to prescribe HAEGARDA for HAE patients beginning the week of April 6th, 2021, using the Factor Concentrates & Other Plasma Protein Order Form. https://www.blood.ca/s/default/files/2021-03/CL_2021-18.pdf Thank you!

Great news for eligible HAE patients in Manitoba! Starting April 1, 2021, Manitoba Pharmacare will list lanadelumab (Takhzyro) as part of Exception Drug Status. To find out more, please make an appointment with your HAE specialist. Thank You!